The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia (Q34746473)

4 August 2017

1 reference

title

The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia (English)

1 reference

4 August 2017

0 references

Karl G Henriksson

1

1 reference

PubMed ID

12122922

4 August 2017

Jan Sörensen

series ordinal

2

1 reference

4 August 2017

1 May 2002

1 reference

Rheumatic Diseases Clinics of North America

4 August 2017

1 reference

4 August 2017

28

1 reference

4 August 2017

2

1 reference

4 August 2017

343-351

1 reference

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

The induction and maintenance of central sensitization is dependent on N -methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Intraplantar injection of dextrorphan, ketamine or memantine attenuates formalin-induced behaviors.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

'Balanced analgesia' in the perioperative period: is there a place for ketamine?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Dependence on dextromethorphan hydrobromide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

The use of NMDA-receptor antagonists in the treatment of chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Successful treatment of postherpetic neuralgia with oral ketamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Low-dose subcutaneous ketamine infusion and morphine tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

NMDA receptor antagonists: interactions with opioids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Dextromethorphan attenuates and reverses analgesic tolerance to morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900013-8

7 January 2021

10.1016/S0889-857X(01)00013-8

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12122922